


KAHF BIOTECH, INC.

Innovative Cancer Therapeutic Developments



kahfbiotech.com Rochester, NY

Highlights

- 1 A novel target in PDAC with limited prior characterization and promising preclinical validation
- 2 Dual therapeutic strategy: blocks metastasis early and kills tumors in late-stage disease
- 3 Capital-efficient plan: lead antibody development achievable with ~\$40-50K
- 4 Platform approach expandable to multiple solid tumors expressing the same receptor
- 5 Lead antibody can be expanded into ADC or Degradable Antibody conjugates (DACs)

- 6 Founded by PhD cancer scientist with deep expertise in cancer therapeutic development platforms

Featured Investor



Ronald L Krall
Syndicate Lead

Follow

Invested \$10,000

Former Chief Medical Officer, GlaxoSmithKline; Head US Development, AstraZeneca Chairman of the Board, Pierian Biosciences Senior Advisor, EIT Pharma

"As a former executive (Chief Medical Officer & Head of Development) with responsibility for medicines development for Zeneca, AstraZeneca and GSK I oversaw the development of more than 20 medicines, including multiple anti-cancer drugs. The research that underpins KAHF's approach to cancer chemotherapy is novel and warrants development investment. An investment to carry this foundational work forwards to try to make a new anti-cancer agent is potentially transformative. The initial target of this development, pancreatic cancer, is undoubtedly one of the cancers most in need of novel therapeutics. KAHF has a path to making a new medicine that is sound and achievable and accounts for the high risk associated with any new drug development. I back KAHF to fulfill the hope of changing the course of cancer."

Team




Muhammad Sadeqi Nezhad CEO

Muhammad Sadeqi Nezhad is the Founder and CEO of KAHF Biotech, Inc., a New York based biotech startup focused on pioneering therapeutic strategies to target

metastatic and dormant cancer cells-areas often overlooked in conventional oncology approaches

kahfbiootech.com

Memo



KAHF Biotech, Inc.

Pioneering next-generation cancer therapies targeting the KAHF receptor to halt tumor progression and metastasis

We named our identified target, KAHF receptor, for confidential purposes

February 2026

KAHF Biotech, Inc. 1

KAHF Biotech, Inc. Overview

- KAHF Biotech is a spinout company from research conducted at the Wilmot Cancer Center in New York—an NCI Designated Cancer Center
- Headquarter, 1200 Jefferson Rd, Suite 210, Rochester, New York 14623
- Our mission is to pioneer next-generation cancer therapies targeting the KAHF receptor to halt tumor progression and metastasis
- Our goal is to develop an optimized Anti-KAHF Monoclonal Antibody as a new biological drug in cancer fields
- Pancreatic Ductal Adenocarcinoma (PDAC) is our lead Cancer type, following with other solid tumors



<https://www.kahfbiootech.com>

Team Members

Founder and CEO



Muhammad Saieqi Nezhad
Ph.D.
Cancer scientist
Specialized in cancer therapeutic development

Scientific Advisor



Darren R. Carpio
M.D., Ph.D.
Surgeon scientist
+20 years of cancer research translational studies

Scientific Advisor



Aram F. Hezel M.D.
Physician scientist
+20 years of cancer research
Specialized in clinical trials

Scientific Advisor



Ronald Lee Kroll M.D.
Physician, Former CMO
+25 years of industry experience
Oversaw 20 drugs approval


KAHF Biotech, Inc.

2


Targeting the KAHF Receptor to Halt Tumor Progression and Metastasis

➤ We named our identified receptor KAHF for confidential purposes

KAHF Receptor Promotes Progression and Metastasis





Anti-KAHF mAb Promotes Tumor Death



KAHF Biotech, Inc.

3

Pancreatic Cancer: A Deadly Disease with No Targeted Solutions



- Second most cause of cancer death by 2030
- 67,440 diagnosis per year in the USA
- 51,980 deaths per year in the USA
- 400,000 diagnosis per year Globally
- Yearly increase rate

- Overall survival of 13%
- Metastatic patient survival 3.1%
- >85% patients diagnosed with metastasis

- Chemotherapy remains standard treatment with response rate of 23-31.6%
- Highly resistance to current therapy
- No Antibody-based therapy
- No Anti-metastasis drug in the field


URGENT NEED TO DEVELOP NOVEL EFFECTIVE THERAPIES!!!

KAHF Biotech, Inc.


4

KAHF Receptor is Highly Expressed by Pancreatic Tumor and Using Anti-KAHF mAb Promotes Tumor Death

1. KAHF Receptor is highly expressed by PDAC Cells




2. Anti-KAHF mAb increases PDAC cell Death



3. KAHF gene plays a survival role in PDAC cells




4. Anti-KAHF mAb Reduces Invasion and basal-like phenotype



KAHF Biotech, Inc.

5


KAHF Receptor Deletion Prevents Metastasis Formation in Genetically Engineered Mouse Models



Targeting the KAHF receptor provides a strong and transformative therapeutic opportunity!!

Proposal: Development of a New High Affinity Anti-KAHF Monoclonal Antibody as a New Biological Drugs in Cancer Fields

- > Sino Biological is the global leader in Antibody fields
- > Provides us the technology with royalty and Ownership free
- > The Antibody Ownership will be transferred to KAHF Biotech, Inc.



We Propose to Develop a Novel, Optimized Anti-KAHF mAb with Improved Affinity for Clinical, IP, and Commercialization Purposes!!!!

Roadmap For Anti-KAHF mAb



This seed round will be used to generate a new patent protected Anti-KAHF mAb ready for IND-enabling studies!!!


Future projections are not guaranteed

Proposed Phase I Clinical Trial

Multi-Center Phase I Trial of Single-Agent Anti-KAHF mAb Therapy

- Primary Endpoints:**
- Incidence and severity of AEs, SAEs, and DLTs
 - Determination of MTD/PP2D
 - Measurement of Anti-KAHF mAb

- Endometrial Cancer
- Stm SCC
- Breast Cancer
- Ovarian Cancer
- Colorectal Cancer
- Bladder Cancer



- Locally advanced solid tumor
- Patients with metastatic tumors
- Progression after systemic therapy
- Dose Escalation (1-20 mg/Kg)
- Single-patient cohorts until a Grade ≥2 toxicity is observed
- Thereafter, 3+3 or modified continual reassessment method (mCRM)
- DLTs are assessed during Cycle 1 (first 28 days)
- Recommended Phase 2 Dose Identified
- Cohort A: Advanced/metastatic solid tumors (pan-tumor)
- Cohort B: KAHF positive patients (>10%)
- Each cohort will enroll up to 15-20 patients

- Immunotherapy with pembrolizumab
- Improved overall survival
- Shrinkage of primary tumor cells
- Reduction in metastatic burden
- Exploratory Endpoint (Pharmacodynamic):
- Changes in tumor EMT signatures, apoptosis, and immune infiltration using RNA-seq and IHC

- Dose escalation: ~20-25 patients
- Expansion cohorts: ~20-30 patients
- Total enrollment: up to 50-60 patients

Our lead antibody has multiple indication-specific pipelines, with each tumor type representing an independent clinical and commercial opportunity!!!

The Market Opportunities

Total Addressable Market (TAM) for PDAC Patients

A proven market for monoclonal antibodies

Global market of \$238B in cancer mAb

TAM (at \$50k-\$150k/patient)
400,000 Patients

Serviceable Available Market (SAM)


30% market share
\$6B-\$18B

Drug (Brand)	Company	Target Protein	2023-2024 Revenue
Keytruda (pembrolizumab)	MERCK	PD-1	\$25.0 B
Opdivo (nivolumab)	Bristol Myers Squibb	PD-1	\$10 B
Darzalex (daratumumab)	Genmab	CD38	\$9.74 B
Vectibix (panitumumab)	AMGEN	EGFR	\$1.05 B
Erbiximab (cetuximab)	Lilly	EGFR	\$1.27 B




Platform Potential: Expanding Our Lead Antibody into Multi-Product Franchise

Antibody Drug Conjugate




Potent tumor killing
Broader indication reach
Second-gen franchise

Degrader Antibody Conjugate



Targeted Degrader delivery
Expanding E3 ligase repertoire
Next-gen immunotherapy


Antibody Oligonucleotide Conjugate



Targeted RNA delivery
Precision gene silencing
Programmable platform

Our lead antibody, Anti-KAHF-mAb, serves as a platform to expand into multiple cancer therapeutic assets!!!





Thank You!

KAHF Biotech is Advancing Next-Generation KAHF-Targeted Therapies to Halt Tumor Progression and Metastasis.

Muhammad Sadeqi Nezhad, Ph.D. CEO

<https://www.kahfbiotech.com>



KAHF Biotech, Inc.

12